|
|
Previous Article | Table of Contents | Next Article 
Blood, Vol. 92 No. 8 (October 15), 1998:
pp. 2766-2770
The Val34Leu Polymorphism in the A Subunit of Coagulation Factor XIII
Contributes to the Large Normal Range in Activity and Demonstrates
That the Activation Peptide Plays a Role in Catalytic Activity
S. Kangsadalampai and
P.G. Board
From the Molecular Genetics Group, John Curtin School of Medical
Research, Australian National University, Canberra, Australia.
There is a wide normal range of coagulation factor XIII activity
that has never been adequately explained. A polymorphism substituting
leucine for valine at position 34 in the activation peptide of the A
subunit of factor XIII has recently been discovered in nondeficient
individuals, and the present studies indicate that the leucine
substitution results in a significant increase in transglutaminase
activity. The frequency of the Leu34 allele in the Australian Caucasian
population is 0.27, which is high enough to suggest that the
inheritance of either the Val34 or Leu34 alleles may contribute to the
wide normal range of activity. Although there has been structural
evidence indicating that the activation peptide does not dissociate
from the enzyme after thrombin cleavage, the discovery of elevated
activity resulting from the Leu34 substitution is the first direct
evidence that the activation peptide plays a continuing role in the
function of factor XIII.
© 1998 by The American Society of Hematology.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
N. Akar, B. Donmez, and G. Deda
FXIII Gene Val34Leu Polymorphism in Turkish Children with Cerebral Infarct
J Child Neurol,
February 1, 2007;
22(2):
222 - 224.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
M. de Lange, T. Andrew, H. Snieder, D. Ge, T. S. Futers, K. Standeven, T. D. Spector, P. J. Grant, and R. A.S. Ariens
Joint Linkage and Association of Six Single-Nucleotide Polymorphisms in the Factor XIII-A Subunit Gene Point to V34L As the Main Functional Locus
Arterioscler Thromb Vasc Biol,
August 1, 2006;
26(8):
1914 - 1919.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. S. Wells, J. L. Anderson, D. K. Scarvelis, S. P. Doucette, and F. Gagnon
Factor XIII Val34Leu Variant Is Protective against Venous Thromboembolism: A HuGE Review and Meta-Analysis
Am. J. Epidemiol.,
July 15, 2006;
164(2):
101 - 109.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R Diz-Kucukkaya, V S Hancer, M Inanc, M Nalcaci, and Y Pekcelen
Factor XIII Val34Leu polymorphism does not contribute to the prevention of thrombotic complications in patients with antiphospholipid syndrome
Lupus,
January 1, 2004;
13(1):
32 - 35.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Butt, H. Zheng, E. Randell, D. Robb, P. Parfrey, and Y.-G. Xie
Combined carrier status of prothrombin 20210A and factor XIII-A Leu34 alleles as a strong risk factor for myocardial infarction: evidence of a gene-gene interaction
Blood,
April 15, 2003;
101(8):
3037 - 3041.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Aleksic, C. Ahn, Y.-W. Wang, H. Juneja, A. R. Folsom, E. Boerwinkle, and K. K. Wu
Factor XIIIA Val34Leu Polymorphism Does Not Predict Risk of Coronary Heart Disease: The Atherosclerosis Risk in Communities (ARIC) Study
Arterioscler Thromb Vasc Biol,
February 1, 2002;
22(2):
348 - 352.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Weger, W. Renner, O. Stanger, O. Schmut, H. Deutschmann, T. C. Wascher, and A. Haas
Role of Factor XIII Val34Leu Polymorphism in Retinal Artery Occlusion
Stroke,
December 1, 2001;
32(12):
2759 - 2761.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. P. Reiner, S. M. Schwartz, M. B. Frank, W.T. Longstreth Jr, L. A. Hindorff, G. Teramura, F. R. Rosendaal, L. K. Gaur, B. M. Psaty, D. S. Siscovick, et al.
Polymorphisms of Coagulation Factor XIII Subunit A and Risk of Nonfatal Hemorrhagic Stroke in Young White Women Editorial Comment
Stroke,
November 1, 2001;
32(11):
2580 - 2587.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Karpati, B. Penke, E. Katona, I. Balogh, G. Vamosi, and L. Muszbek
A Modified, Optimized Kinetic Photometric Assay for the Determination of Blood Coagulation Factor XIII Activity in Plasma
Clin. Chem.,
December 1, 2000;
46(12):
1946 - 1955.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Balogh, G. Szoke, L. Karpati, U. Wartiovaara, E. Katona, I. Komaromi, G. Haramura, G. Pfliegler, H. Mikkola, and L. Muszbek
Val34Leu polymorphism of plasma factor XIII: biochemistry and epidemiology in familial thrombophilia
Blood,
October 1, 2000;
96(7):
2479 - 2486.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. A. S. Ariens, H. Philippou, C. Nagaswami, J. W. Weisel, D. A. Lane, and P. J. Grant
The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure
Blood,
August 1, 2000;
96(3):
988 - 995.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Lane and P. J. Grant
Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease
Blood,
March 1, 2000;
95(5):
1517 - 1532.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Elbaz, O. Poirier, S. Canaple, F. Chedru, F. Cambien, and P. Amarenco
The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction
Blood,
January 15, 2000;
95(2):
586 - 591.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. A. S. Ariens, H. P. Kohler, M. W. Mansfield, and P. J. Grant
Subunit Antigen and Activity Levels of Blood Coagulation Factor XIII in Healthy Individuals : Relation to Sex, Age, Smoking, and Hypertension
Arterioscler Thromb Vasc Biol,
August 1, 1999;
19(8):
2012 - 2016.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Anwar, L. Gallivan, S. D. Edmonds, and A. F. Markham
Genotype/Phenotype Correlations for Coagulation Factor XIII: Specific Normal Polymorphisms Are Associated With High or Low Factor XIII Specific Activity
Blood,
February 1, 1999;
93(3):
897 - 905.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. A. Trumbo and M. C. Maurer
Examining Thrombin Hydrolysis of the Factor XIII Activation Peptide Segment Leads to a Proposal for Explaining the Cardioprotective Effects Observed with the Factor XIII V34L Mutation
J. Biol. Chem.,
June 30, 2000;
275(27):
20627 - 20631.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Sadasivan and V. C. Yee
Interaction of the Factor XIII Activation Peptide with alpha -Thrombin. CRYSTAL STRUCTURE OF ITS ENZYME-SUBSTRATE ANALOG COMPLEX
J. Biol. Chem.,
November 17, 2000;
275(47):
36942 - 36948.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|